

Click for [Full Prescribing Information](#) including **BOXED WARNING**, if applicable.



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

March 28, 2022


**Notification of Label Change for
Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL) Multiple Dose Vial**

Dear Customer,

Please be advised that Pfizer Hospital has modified the label of **Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL) Multiple Dose Vial**, NDC 61703-0350-38 to add additional information.

The new label now includes “2 mL Multiple-dose Vial” above the drug name, and “For Intravenous, Intramuscular and Subcutaneous Use Only” below “Contains preservative Cytotoxic Agent” (in red) as seen in the current and new images below. Customers may begin to receive product with the new label as soon as early as Q2 2022.

LABELS



There is no change to the NDC number, pricing, indication or formulation of this product. In addition, please note that the packaging of other Methotrexate presentations produced by Pfizer Hospital are not changing at this time.

If you have any questions regarding this notification, please contact our Customer Service Department at 1-844-646-4398 or via email at PICustomerServices@pfizer.com.

Thank you,

Matt Kreiter
Director, Oncology and Alternate Site
Pfizer Hospital Business Unit